Clinical Trials Logo

Clinical Trial Summary

Any pathogen that causes an upper respiratory tract infection can cause bronchitis.The primary pathogen is virus. On the basis of virus infection, pathogenic bacteria may cause secondary infection or co-infection。Xiyanping injection is mainly used in the treatment of bronchitis by intravenous injection。


Clinical Trial Description

To further verify the clinical value and safety of intramuscular injection of Xiyanping injection in the treatment of acute bronchitis in children, provide reference for subsequent validation studies, and provide more reasonable and standard application guidance and basis for clinical practice.A multicenter, randomized, parallel controlled study was conducted on the treatment of acute bronchitis by intramuscular injection of Xiyanping injection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04926506
Study type Interventional
Source Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Contact
Status Not yet recruiting
Phase N/A
Start date October 8, 2021
Completion date December 30, 2022